New tafamidis tablet could be easier to swallow
NCT ID NCT07587697
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial compares a new orally disintegrating tablet (ODT) of tafamidis to the standard capsule in 15 healthy adults. Participants receive single doses of each form under fasting conditions to measure drug levels in the blood. The goal is to see if the ODT works the same as the capsule, potentially offering a more convenient option for patients who have trouble swallowing pills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tafamidis
What this could lead to
If successful, this could show that the new orally disintegrating tablet works as well as the current capsule, offering a more convenient option for patients.
What could go wrong
This is a very early, small study in healthy people, not patients. It only checks blood levels, not whether the drug actually treats disease. The new form might not prove equivalent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
P-One Clinic
Hachioji-shi, Tokyo, 1920071, Japan